DHEA-S Medication-Driven Changes: What Raises, Lowers, and Optimizes Your Levels

The direct answer

DHEA-S is not a single-cause lab value. It reflects adrenal androgen output, and that output is sensitive to drugs that suppress the hypothalamic-pituitary-adrenal (HPA) axis, particularly corticosteroids, and to a lesser and less consistently documented degree, chronic opioids, some antipsychotics, and insulin resistance. Oral DHEA supplementation raises DHEA-S in a dose-dependent way and is the only intervention discussed here with direct, repeated trial evidence behind it; weight loss and metformin have plausible but more modest and less consistently replicated effects. No medication or supplement listed here has been shown in a randomized trial to change hard outcomes, such as fractures, cardiovascular events, or mortality, by way of raising or lowering DHEA-S. The clinically useful move is to interpret an abnormal DHEA-S in the context of the full medication list before assuming primary adrenal disease.

Why DHEA-S is used as a marker, and what it is not

DHEA-S is produced almost entirely by the adrenal zona reticularis and circulates as a precursor that peripheral tissues convert into androgens and estrogens. It is measured far more often than free DHEA because its longer half-life makes it a stable, time-of-day-independent blood test, whereas free DHEA fluctuates with each ACTH pulse over a matter of minutes. For that reason, DHEA-S, not free DHEA, is the analyte to track when a clinician wants to know whether a medication change has affected adrenal androgen output.

DHEA-S levels are highest in the mid-20s and decline over subsequent decades. This decline, sometimes called adrenopause, has been linked in observational cohorts to lower muscle mass, reduced libido, fatigue, and altered immune markers. That correlation is well described in aging research, but it does not establish that restoring DHEA-S to a younger person's level would reverse any of those changes. Treat the decline as a marker of biological aging to note, not a deficiency to automatically correct.

What counts as a normal range, and why "optimal" is a different question

Reference ranges describe what is statistically common in a screened, generally healthy population, stratified by age and sex because DHEA-S falls steadily across adulthood in both. Commercial labs (for example Quest Diagnostics and LabCorp) publish their own age- and sex-banded intervals, and these intervals differ somewhat between labs and assay platforms. There is no single universally agreed number; the reference range printed on your own lab report, from your own lab's assay, is the one that applies to your result. Age-banded DHEA-S ranges of the kind circulated in patient-facing material (broadly: several hundred mcg/dL in young adulthood in men, falling to double digits by the seventh and eighth decades, with women's values roughly half of men's at each age band) are consistent with the general pattern described in longitudinal aging literature, but exact cutoffs should be verified against the specific assay and population before being quoted as clinical fact.

"Optimal" is a separate and less settled concept. Longevity-oriented practice sometimes targets the upper third of the age-matched reference range as an aspirational goal. This is a clinical judgment, not a guideline-endorsed threshold, and no randomized controlled trial has shown that pushing DHEA-S toward a younger person's level reduces cardiovascular events, fractures, or mortality in an otherwise healthy adult. Readers should treat any specific "optimal" number offered by a clinic or supplement seller as a hypothesis, not a validated target.

What reliably lowers DHEA-S

Corticosteroids, at any dose and by any route, are the most consistently documented suppressor of DHEA-S. Exogenous corticosteroids suppress ACTH through HPA-axis negative feedback, and because DHEA-S synthesis depends on tonic ACTH stimulation, oral, inhaled, topical, and intranasal steroids can all reduce it. This is the single best-established mechanism in this article, drawn from decades of endocrinology literature on iatrogenic adrenal suppression, though the exact magnitude of suppression for any specific steroid, dose, and duration should be checked against current literature rather than assumed from a single historical study.

Chronic opioid therapy is associated with HPA-axis and gonadal suppression broadly, and several small studies have reported lower DHEA-S in long-term opioid users, with higher morphine-equivalent doses associated with greater suppression. Opioid-induced adrenal insufficiency is under-recognized clinically; a low DHEA-S alongside unusual fatigue or recurrent infection in a patient on medium-to-high dose chronic opioids is a reasonable trigger to check morning cortisol as well, rather than to assume DHEA-S alone tells the whole story.

Some second-generation antipsychotics, particularly those with strong dopamine D2 blockade such as risperidone, have been associated with reduced DHEA-S in small studies, plausibly through the same prolactin-raising, gonadal- and adrenal-androgen-suppressing pathway that produces their known reproductive endocrine side effects. The specific percentage reductions reported in small single-center studies should not be treated as precise, generalizable numbers without checking the primary literature.

Insulin resistance and hyperinsulinemia are inversely associated with DHEA-S in population data, though the mechanism is not fully resolved; proposed pathways include direct suppression of zona reticularis activity or IGF-1-mediated effects. This is an association, not a demonstrated causal suppression, and should be described that way to patients.

Systemic ketoconazole is a special case worth naming separately: it blocks multiple steps of adrenal steroidogenesis directly and is a recognized cause of substantial, rapid drops in adrenal steroid output, including DHEA-S, when used at antifungal treatment doses. This is a pharmacologic mechanism (enzyme inhibition), not an indirect HPA-axis effect, and is worth distinguishing from the corticosteroid and opioid mechanisms above.

What can raise DHEA-S, and how strong the evidence is for each

Oral DHEA supplementation is the most direct and best-studied way to raise DHEA-S, and the DHEAge Study (a French placebo-controlled trial in older adults, published around 2000) is the most frequently cited trial in this area, reporting that daily oral DHEA over about a year raised serum DHEA-S from low, age-typical baseline values into the range seen in young adults, in both men and women. The exact dose-response numbers from that and similar trials should be verified against the primary paper before being quoted precisely in a clinical document; what is well established is the direction and general size of the effect, that oral DHEA reliably and substantially raises DHEA-S. What is not established is that doing so improves hard outcomes in otherwise healthy older adults. The Endocrine Society's guidance on androgen therapy in women has recommended against routine DHEA prescription outside the setting of documented adrenal insufficiency, reflecting a gap in efficacy evidence for healthy aging rather than a specific safety signal.

Weight loss is associated with higher DHEA-S, most plausibly because DHEA-S metabolic clearance is accelerated by adipose tissue mass, so meaningful weight loss (including with GLP-1 receptor agonists such as semaglutide or tirzepatide) would be expected to raise DHEA-S through reduced clearance rather than increased adrenal production. Direct dedicated endocrine substudies quantifying this effect for GLP-1 therapy specifically should be checked before quoting an exact mcg/dL-per-kilogram figure; the mechanism is plausible and consistent with general endocrinology, but the size of the effect in GLP-1 trials is not something this article can confirm from verified primary sources.

Metformin has shown a modest DHEA-S increase in at least one small randomized trial in women with PCOS, plausibly through improved insulin sensitivity reducing hyperinsulinemia-driven suppression of the zona reticularis. This is not a primary reason to prescribe metformin, and the effect size reported in any single small trial should not be generalized to all patients or presented as a precise, reproducible number without checking the original study.

Testosterone replacement therapy (TRT) in men has an inconsistent relationship with DHEA-S across studies; some show a small decrease, others no significant change. Clinicians should not assume TRT will correct a low DHEA-S. If adrenal androgen deficiency and hypogonadism coexist, they may need to be addressed as separate issues.

Hormone replacement therapy (HRT) in women depends heavily on formulation. Oral estrogen increases sex hormone-binding globulin and has been associated with somewhat lower DHEA-S in population studies, plausibly through modest ACTH suppression or altered hepatic metabolism. Transdermal estrogen, which bypasses first-pass hepatic metabolism, appears closer to neutral for DHEA-S in available data. Women on oral HRT with persistent fatigue or low libido despite adequate estradiol and testosterone levels are a reasonable population in whom to recheck DHEA-S, though the size of any HRT-related suppression reported in specific cohort studies should be verified before quoting a precise percentage.

Decision framework: what to do with an unexpected DHEA-S result on a medicated patient

This framework is for interpreting an outlier DHEA-S value in a patient who is on one or more of the medications discussed above. It does not replace clinical judgment, and it does not substitute for an ACTH stimulation test or endocrinology referral when adrenal insufficiency is suspected.

Interpreting a low DHEA-S with a normal cortisol

A low DHEA-S paired with a normal morning cortisol is not, on its own, evidence of adrenal insufficiency. It more plausibly reflects selective decline of the zona reticularis, a pattern seen with normal aging, chronic low-grade inflammation, and several of the medications above. Some functional medicine practices use a cortisol-to-DHEA-S ratio as an informal marker of chronic stress burden. This ratio has no validated diagnostic threshold in mainstream endocrinology guidelines, and a specific numeric cutoff should not be presented to patients as an established clinical marker.

Safety considerations for oral DHEA supplementation

Oral DHEA is sold over the counter in the United States and is not a controlled substance, which increases the chance of unsupervised, higher-than-studied dosing. Known and plausible risks, drawn from the general pharmacology of an androgen precursor rather than from a single verified trial, include:

• Androgenic effects in women: acne, oily skin, and unwanted hair growth, through peripheral conversion to testosterone and dihydrotestosterone, more likely at higher doses.
• Estrogenic effects in men: DHEA converts to estradiol via aromatase, and gynecomastia has been reported in men taking higher oral doses.
• Hormone-sensitive cancer risk: DHEA is generally considered contraindicated, or at minimum requiring close specialist input, in anyone with a personal or strong family history of hormone-sensitive cancers, including ER-positive breast cancer, ovarian cancer, or prostate cancer, because it is a precursor to both androgens and estrogens.
• Regulatory status: The FDA has not approved oral DHEA as a drug for aging, adrenopause, or general wellness indications; it is regulated as a dietary supplement. A separate FDA-approved product, prasterone (brand name Intrarosa), is a low-dose vaginal insert approved specifically for painful intercourse (dyspareunia) related to menopause; its systemic absorption and effect on serum DHEA-S are minimal compared with oral supplementation, and it should not be confused with over-the-counter oral DHEA capsules. (Regulatory status as of this review; confirm current FDA labeling before relying on this for a specific patient.)

Anyone starting or continuing oral DHEA, particularly at doses above what is typically studied for adrenal insufficiency, should discuss monitoring with a clinician, including periodic testosterone, estradiol, and (in men) PSA, alongside DHEA-S itself.

What is established, what is plausible, and what is not established

Established: Corticosteroids, through any delivery route, suppress the HPA axis and can lower DHEA-S; this is a well-described pharmacologic mechanism, not a novel or disputed claim. DHEA-S has a much longer half-life than free DHEA and is the preferred analyte for monitoring adrenal androgen status because it does not require fasting or precise timing. Oral DHEA supplementation reliably raises DHEA-S in a dose-related way.

Plausible but not firmly established: That chronic opioids, certain antipsychotics, and insulin resistance meaningfully lower DHEA-S in a way that matters clinically for an individual patient; the supporting studies are generally small, and effect sizes vary. That weight loss from GLP-1 receptor agonists raises DHEA-S through reduced metabolic clearance; the mechanism is reasonable but the magnitude in current GLP-1 trial populations has not been independently verified here. That metformin modestly raises DHEA-S in PCOS.

Not established: That restoring DHEA-S to a "youthful" or "optimal" level, by any means, improves hard outcomes such as fracture risk, cardiovascular events, cognitive decline, or mortality in generally healthy adults. That a specific cortisol-to-DHEA-S ratio threshold has diagnostic meaning. That any precise percentage reduction or increase quoted for a specific drug and dose in older single studies is directly generalizable to a given patient without checking the primary literature.

When to seek urgent or specialist evaluation

A very low DHEA-S combined with low morning cortisol, fatigue, weight loss, or hypotension warrants prompt evaluation for adrenal insufficiency, which can be a medical emergency in its acute form (adrenal crisis) and is not something to manage through supplement adjustment alone. A very high DHEA-S, particularly with signs of rapid virilization or a value markedly above the age-matched reference range, warrants adrenal imaging to rule out adrenocortical carcinoma or congenital adrenal hyperplasia, and should not be assumed to be a benign PCOS-related elevation without further workup.

A note on sourcing: while research on DHEA-S levels, the DHEAge trial, corticosteroid-suppression protocols, and psychiatric medication studies represents genuine published work, we were unable to independently verify specific citations, dosing parameters, and quantitative outcomes from earlier versions against original sources during this update. For this reason, numerical statements have been qualified or marked with appropriate caution. Readers who intend to use this information for clinical decisions or dosing recommendations should review the primary studies themselves rather than relying on our summary of the data.